---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effect on quality measures"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effect on quality measures. Topics: MIPS Quality ID 453: systemic cancer-directed therapy in the last 14 days of life, MIPS Quality ID 457: hospice admission for less than 3 days before death, MIPS Quality ID 143: pain intensity quantified, MIPS Quality ID 144: plan of care for pain, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Palazestrant on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### MIPS Quality ID 453: systemic cancer-directed therapy in the last 14 days of life

> “Percentage of patients who died from cancer receiving systemic cancer-directed therapy in the last 14 days of life.”
> “Do not include supportive care therapies (e.g., growth factors, bisphosphonates, RANK ligand inhibitors, nausea medications or fluids if these are not given in association with”
> “Hormonal therapies and steroids are not included in this systemic cancer directed therapy definition.”

Source: [CMS Quality ID 453 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_453_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

### MIPS Quality ID 457: hospice admission for less than 3 days before death

> “Percentage of patients who died from cancer and admitted to hospice and spent less than 3 days there.”

Source: [CMS Quality ID 457 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_457_MIPSCQM.pdf)

<a id="topic-2.1.2.13-3"></a>

### MIPS Quality ID 143: pain intensity quantified

> “Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified.”
> “Patient on oral chemotherapy on or within 30 days before denominator eligible encounter: M1433”

Source: [CMS Quality ID 143 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_143_MIPSCQM.pdf)

<a id="topic-2.1.2.13-4"></a>

### MIPS Quality ID 144: plan of care for pain

> “Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain with a documented plan of care to address pain.”
> “Patient on oral chemotherapy during the performance period: M1435”

Source: [CMS Quality ID 144 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_144_MIPSCQM.pdf)

<a id="topic-2.1.2.13-5"></a>

### MIPS Quality ID 047: advance care plan

> “Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan.”

Source: [CMS Quality ID 047 (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_047_MIPSCQM.pdf)

<a id="topic-2.1.2.13-6"></a>

### Enhancing Oncology Model: episodes with hormonal therapy only and quality strategy

> “Unlike OCM, EOM focuses on beneficiaries receiving systemic initiating cancer therapy, and will not include beneficiaries who receive hormonal therapy only.”
> “Subject to certain exceptions, EOM includes the following seven cancer types for beneficiaries undergoing systemic initiating cancer therapy: high-risk breast cancer, chronic leukemia, small intestine/colorectal cancer, lung cancer, lymphoma, multiple myeloma, and high-intensity prostate cancer.”
> “The EOM quality strategy focuses on measures from the following domains: patient experience, avoidable acute care utilization, management of symptoms and toxicity, management of psychosocial health, and management of end-of-life care.”

Source: [CMS Enhancing Oncology Model FAQ (2026)](https://www.cms.gov/eom-frequently-asked-questions)

<a id="topic-2.1.2.13-7"></a>

### Product-specific effect on quality measures

No evidence found.

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
